Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Recruiting now Phase 3 NCT06568367
Run by Axsome Therapeutics, Inc. · for 18 to 65 · All sexes
What this study is about
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).
Who can join (things the study team will check)
✅ You may be able to join if…
- Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD)
- Provides written informed consent to participate in the study before the conduct of any study procedures.
- Male or female, aged 18 to 65 inclusive.
🚫 You may not be able to join if…
- Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
- Unable to comply with study procedures.
- Medically inappropriate for study participation in the opinion of the investigator.
Where this trial is running
- Clinical Research Site, Cullman, Alabama, United States
- Clinical Research Site, Chandler, Arizona, United States
- Clinical Research Site, Tucson, Arizona, United States
- Clinical Research Site, Little Rock, Arkansas, United States
- Clinical Research Site, Cerritos, California, United States
- Clinical Research Site, Chula Vista, California, United States
- Clinical Research Site, Huntington Beach, California, United States
- Clinical Research Site, Long Beach, California, United States
- Clinical Research Site, Santa Ana, California, United States
- Clinical Research Site, Colorado Springs, Colorado, United States
- Clinical Research Site, Brandon, Florida, United States
- Clinical Research Site, Hialeah, Florida, United States
+ 28 more sites.
Who to contact
Study Director · 212-332-5061 · sol-swd-301@axsome.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06568367.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.